Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AGM Presentation

November 5, 2024

Phase II ABSSSI Clinical Trial Advances to Final Stages

November 4, 2024

Efficacy Data & Approval to Continue Ph II ABSSSI Trial

October 27, 2024

Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

October 8, 2024

Notice of Special General Meeting/Proxy Form

October 8, 2024

Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan

August 6, 2024

Successful Completion of Share Purchase Plan

August 4, 2024

Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel

July 16, 2024

US Department of Defense Grants US $2m for R327G

July 15, 2024

R327 Efficacy against WHO Priority Pathogen Acinetobacter B

July 8, 2024

Placement & SPP to raise $10 million - Funded to FY26

July 2, 2024

Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete

June 27, 2024

Ethics Approval Broadens to All Topical Infections

June 24, 2024

Further R&D Rebate Approved

June 18, 2024

R327 added to WHO List of Antibacterial Products

June 18, 2024

Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

June 10, 2024

Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort

May 15, 2024

MCRI Pilot Study- Positive Efficacy Data for Lung Infections

May 9, 2024

China Patent Granted for RECCE Anti-Infectives

May 6, 2024

Safety Committee Approves High Dose of 4,000mg

April 26, 2024

Recce Completes 5,000 R327 Doses Per Week under GMP

April 16, 2024

Recce Pharmaceuticals - Business Update

April 7, 2024

Patent Granted in Israel for RECCE Anti-Infectives

April 2, 2024

Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial

March 12, 2024

Recce Receives AUD $11.17m R&D Advance

March 7, 2024

Safety Committee Approves Expansion of Ph I/II DFI Trial

February 25, 2024

RCE Establishes Strategic Partnership in South-East Asia

February 5, 2024

Positive Ph I/II DFI Efficacy Data to Support Site Expansion

January 17, 2024

Murdoch Children's R327 Efficacy UTI in-vivo

December 27, 2023

RCE Awarded Further $11.17m Advanced Overseas Finding

December 15, 2023

RCE Awarded $43.7m AusIndustry Advanced Overseas Finding

December 14, 2023

Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo

December 13, 2023

Canadian Patent Granted for RECCE Anti-Infectives

November 22, 2023

Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial

November 6, 2023

Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis

October 23, 2023

Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial

September 22, 2023

Placement and Entitlement Offer

September 11, 2023

Opening R&D Address at World AMR Congress

September 7, 2023

RECCE Trademark Registered - Vietnam

September 6, 2023

Additional Positive Patient Cases - Special Access Scheme

August 31, 2023

Appendix 4E and Unaudited Preliminary Report

August 31, 2023

Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial

August 28, 2023

Patients Dosed in R327 Diabetic Foot Infection Trial

August 22, 2023

Phase I/II Burn Wound Infection Trial Stage 1 Complete

August 21, 2023

Positive Patients Update - Special Access Scheme

August 7, 2023

Australian Patent Granted for RECCE Anti-Infectives

August 3, 2023

Bonus Canadian R&D Rebate Received

July 28, 2023

Scientia Completes Cohort Dosing in Phase I/II UTI Trial

July 28, 2023

Scientia Doses Ahead of Schedule in Phase I/II UTI Trial

July 24, 2023

Clarification - 5x Higher Concentration in Urine & Plasma

July 20, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 26 decks. Every deck is listed under its year.